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Abstract
The majority of patients with mild traumatic brain injury (mTBI) will have normal Glasgow
coma scale (GCS) of 15. Furthermore, only 5%–8% of them will be CT-positive for an mTBI.
Having a useful biomarker would help clinicians evaluate a patient’s risk of developing intra-
cranial lesions. The S100B protein is currently the most studied and promising biomarker for
this purpose. Heart fatty-acid binding protein (H-FABP) has been highlighted in brain injury
models and investigated as a biomarker for stroke and severe TBI, for example. Here, we
evaluate the performances of S100B and H-FABP for differentiating between CT-positive
and CT-negative patients. A total of 261 patients with a GCS score of 15 and at least one
clinical symptom of mTBI were recruited at three different European sites. Blood samples
from 172 of them were collected 6 h after trauma. Patients underwent a CT scan and
were dichotomised into CT-positive and CT-negative groups for statistical analyses. H-
FABP and S100B levels were measured using commercial kits, and their capacities to
detect all CT-positive scans were evaluated, with sensitivity set to 100%. For patients
recruited 6 h after trauma, the CT-positive group demonstrated significantly higher levels
of both H-FABP (p = 0.004) and S100B (p = 0.003) than the CT-negative group. At 100%
sensitivity, specificity reached 6% (95% CI 2.8–10.7) for S100B and 29% (95% CI 21.4–
37.1) for H-FABP. Similar results were obtained when including all the patients recruited, i.e.
hospital arrival within 24 h of trauma onset. H-FABP out-performed S100B and thus seems
to be an interesting protein for detecting all CT-positive mTBI patients with a GCS score of
15 and at least one clinical symptom.
PLOS ONE | https://doi.org/10.1371/journal.pone.0175572 April 18, 2017 1 / 11
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Lagerstedt L, Egea-Guerrero JJ,
Bustamante A, Montaner J, Rodrı´guez-Rodrı´guez
A, El Rahal A, et al. (2017) H-FABP: A new
biomarker to differentiate between CT-positive and
CT-negative patients with mild traumatic brain
injury. PLoS ONE 12(4): e0175572. https://doi.org/
10.1371/journal.pone.0175572
Editor: Firas H. Kobeissy, University of Florida,
UNITED STATES
Received: September 15, 2016
Accepted: March 28, 2017
Published: April 18, 2017
Copyright: © 2017 Lagerstedt et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
in the paper and its Supporting Information files.
Funding: The authors received no specific funding
for this work.
Competing interests: The authors have declared
that no competing interests exist.
Introduction
Mild traumatic brain injury (mTBI) is common worldwide, with an annual incidence esti-
mated to be above 600/100,000 individuals.[1] Clinicians diagnose and distinguish mTBI
patients at risk of intracranial lesions using the Glasgow coma scale (GCS) and clinical symp-
toms such as headache, nausea, vomiting, loss of consciousness and amnesia.[2,3] The GCS is
used to estimate the conscious state and patients scoring between 13 and 15 are classified as
having mTBI; indeed the majority of mTBI cases have the GCS best response score of 15.[3]
Subsequently, CT scans are often performed to exclude or confirm the existence of brain
lesions due to the trauma. However, CT scans are harmful to patients, costly and only a few
patients will actually have a brain lesion (5%–8%).[3,4] Developing decision rules for safely
distinguishing between patients who will turn out to be CT-positive and CT-negative could
help to avoid many unnecessary CT scans.
Several guidelines have put forward decision rules for handling mTBI patients, based pri-
marily on the GCS and risk factors (e.g. clinical symptoms).[3,5] However, this still means that
every patient with a symptom will probably undergo a CT-scan. Another approach, which has
been widely studied, is the use of blood-based biomarkers. The individual performances of
GFAP, Tau and UCHL-1, among others, have all been investigated, though S100B remains the
most-studied protein biomarker.[6–16] Moreover, to avoid CT-negative scans, the Scandina-
vian guideline suggests combining clinical criteria and measuring S100B (cut-off 0.1 μg/L).
[5,15] However, the Eastern Association for the Surgery of Trauma guidelines indicate that
S100B should not be relied upon for making such a decision.[17] There remains a need to fur-
ther investigate S100B’s effectiveness (or that of other biomarkers), in conjunction with clinical
risk factors, at differentiating between CT-positive and CT-negative patients.
Previous studies on brain injury models have revealed heart fatty-acid binding protein
(H-FABP) to be a potentially significant brain injury biomarker.[18,19] It has been shown to
be located in the heart but also in the brain and described as an interesting diagnostic marker
in stroke, Creutzfeldt-Jakob, Alzheimer’s and Parkinson’s diseases, subarachnoid haemorrhage
and severe TBI.[18,20–23] In stroke, H-FABP has a rapid increase in concentration with a
peak at 3h after symptom onset and thereafter the concentrations remained high for 5 days.
[20] The early increase of blood concentration and steadiness in time make this protein a
potential interesting tool for brain lesion diagnostics. Furthermore, H-FABP has already been
shown to be able to differentiate between controls and mTBI patients.[23] It thus seemed
worthwhile to investigate H-FABP’s effectiveness further as a potential diagnostic tool for dif-
ferentiating between the CT scan results of mTBI patients. Therefore, the aim of this prospec-
tive multicentre study was to evaluate and compare the capacities of H-FABP and S100B in
discriminating between CT-positive and CT-negative patients with a GCS score of 15 and at
least one additional clinical symptom.
Methods
Inclusion and exclusion criteria
This study recruited a total of 261 patients at three different European sites: Geneva (Switzer-
land), Barcelona (Spain) and Seville (Spain). Written informed consent was obtained from all
patients, or their legal representatives, prior to inclusion. Children (< 18 years) were included
only after written informed consent from a parent or next-of-kind. To participate, patients
needed to fulfil several inclusion criteria: diagnosis of mTBI with a GCS score of 15; presence
of at least one clinical symptom (loss of consciousness, amnesia, vomiting or nausea, headache
or equilibrium disorder); CT scan performed within 24 h of the trauma (where the presence of
H-FABP: A mTBI biomarker for CT-scans
PLOS ONE | https://doi.org/10.1371/journal.pone.0175572 April 18, 2017 2 / 11
epidural haemorrhage, subdural haemorrhage, subarachnoid haemorrhage, intracerebral
haemorrhage, contusion with haemorrhage, cerebral oedema or skull fracture was classified
as CT-positive); blood sample collected at admission; and age above 14 years old. Exclusion
criteria were: pregnancy; GCS score below 15 at admission to hospital; absence of clinical
symptoms; no head CT scan; and no signed informed consent form. The study was approved
by the relevant local ethics committees: Geneva’s Human Research Ethics Committee (CER:
12–194 / NAC 12–074); Barcelona’s Hospital Universitari Vall d’Hebron Ethics Committee
(PR_AG_195–2012); and Seville’s Virgen del Rocı´o University Hospital Institutional Review
Board (2012PI/120).
H-FABP and S100B assays
Upon hospital arrival, each patient had a serum (Seville and Barcelona) or plasma (Geneva)
sample withdrawn, centrifuged, aliquoted and stored at -80˚C until analysis. Both H-FABP
and S100B were analysed according to the manufacturer’s recommendations. For patients
recruited in Geneva, H-FABP was measured using a HK402 kit from Hycult (Hycult Biotech,
Uden, The Netherlands) with a limit of quantification (LOQ) ranging between 102–25000
pg/mL, and for patients recruited in Spain it was measured using a K151HTD kit from Meso
Scale (Meso Scale Diagnostics, Rockville, MD, USA) LOQ 137–100000 pg/mL. For patients
recruited in Geneva and Barcelona, S100B was measured using an EZHS100B-33K kit from
Millipore (Millipore, Billerica, MA, USA) LOQ 2.7–2000 pg/mL, and in Seville it was mea-
sured using an Elecsys 2010 immunoassay system (Roche Diagnostics, Germany) LOQ 0.005–
39 μg/L. Results are presented in ng/mL for H-FABP and μg/L for S100B.
Statistical analysis
The results from the three sites were merged to form one large multicentre study. Given the
heterogeneity in the three cohorts, in terms of the samples (serum and plasma) and assays
used, the biomarker results were merged by normalisation, using the median or the z-score as
correction factors. This provided comparable results. Patients were dichotomised into CT-pos-
itive and CT-negative groups for statistical analyses. As S100B and H-FABP data were non-
parametrically distributed, as shown by the Kolmogorov-Smirnov test (p< 0.001), the differ-
ence between groups was established using non-parametric Mann-Whitney U tests. Fisher’s
exact test and the chi-square test were used to identify significant differences in clinical data
between the CT groups, and Spearman rank correlation test was used for correlation between
continuous data. The results were further stratified by those clinical factors found to be signifi-
cantly different in the CT-positive and CT-negative groups. IBM SPSS software, version 20.0
(SPSS Inc., Chicago, IL, USA), was used for all the statistical analyses. The proteins’ diagnostic
performances were tested using receiver operating characteristics (ROC) curves with TIBCO
Spotfire S+1 version 8.2 softeware (TIBCO software Inc., Palo Alto, CA, USA). For each pro-
tein, the thresholds were selected at the best cut-off for a sensitivity of 100% and 90%–100%.
Results
The present study included 261 mTBI patients with a GCS score of 15. Of these, 172 patients
came to the hospital 6 h after trauma, with a mean time (± SD) of 198 min ± 88. The most
common clinical symptoms were a loss of consciousness and amnesia (Table 1). A total of 32
patients (19%) were classified as CT-positive, the majority of whom (72%) were men. The
most frequent CT-findings were subarachnoid haemorrhage and skull fractures (Table 2). Age
was the only clinical variable found to be significantly different between CT-positive and CT-
negative patients (p = 0.001) (Table 1). Comparable demographics were also obtained for each
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cohort separately with only minor differences such as age and the percentage of isolated brain
injuries (S1–S3 Tables).
S100B and H-FABP levels were measured for all patients (at t 6 h) and showed signifi-
cantly higher concentrations in CT-positive than in CT-negative patients (p = 0.003 and
p = 0.004, respectively). The proteins were also investigated for their individual performances.
S100B was first evaluated at the cut-off level of 0.1 μg/L, as previously suggested by Scandina-
vian guidelines.[5] At this cut-off, S100B showed 42% specificity and 81% sensitivity (Fig 1 and
Table 3). With sensitivity set at 100%, S100B displayed a specificity of 6% and H-FABP dis-
played a specificity of 29%. From a test point of view, investigated using their negative and pos-
itive predictive values (NPV and PPV), both proteins displayed an NPV of 100%. For the PPV,
Table 2. CT-scan findings detected in CT-positive mTBI patients.
CT-scan findings Yes, n
Subarachnoid haemorrhage 15
Subdural haemorrhage 9
Intracerebral haemorrhage 4
Epidural haemorrhage 2
Contusion with haemorrhage 9
Edema 1
Skull fracture 15
https://doi.org/10.1371/journal.pone.0175572.t002
Table 1. Characteristics of mTBI patients, 6 h post-trauma.
CT- CT+ p-value†
CT scan, n (%) 140 (81) 32 (19)
Trauma to blood sample (min) 0.818‡
Mean (SD) 199 (86) 194 (96)
Median (min.–max.) 203 (35–360) 208 (40–360)
Age (years), mean (SD) 46 (20) 61 (25) 0.001‡
Male, n (%) 101 (72) 23 (72) 0.976
Symtoms, y (%)
Amnesia 84 (60) 24 (75) 0.113
LOC 113 (81) 27 (84) 0.631
Nausea/vomiting 31 (22) 9 (28) 0.47
Headache 59 (42) 8 (25) 0.073
Impaired equilibrium 2 (1) 0 (0) 1
Mechanism of Injury, n (%)
Traffic accident 36 (26) 10 (31) 0.523
Fall 52 (37) 10 (31) 0.531
Assault 25 (18) 5 (16) 0.764
Sports 4 (3) 1 (3) 0.648
Others 19 (14) 6 (19) 0.307
NA 4 (3)
Isolated brain trauma, y (%) 100 (72) 24 (75) 0.727
NA 1 (1)
† Chi-square test or Fisher’s exact test
‡ Mann-Whitney U test
NA: not available
https://doi.org/10.1371/journal.pone.0175572.t001
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H-FABP reached 22%, whereas S100B remained below 20%. The proteins were also evaluated
for their best performance when sensitivity was set in the 90%–100% range. In this case, S100B
reached 19% specificity, but at the cost of its sensitivity dropping to 91%. There was no
observed change in performance for H-FABP (100% sensitivity and 29% specificity).
The H-FABP and S100B markers were further evaluated in combination. Patients were clas-
sified as CT-positive when S100B> 0.042 μg/L and H-FABP > 2.620 ng/mL. Compared to the
H-FABP alone, the panel slightly increased specificity, to 30%, with sensitivity remaining at
100%.
CT-positive patients were found to be significantly older than CT-negative patients
(p = 0.001) (Table 1). When age was tested as an individual parameter, it reached an AUC of
68%. A sensitivity of 100% could not be attained, indicating that age alone has a low value in
identifying CT-positive patients. Significant, though minor, correlations were found between
both S100B and age (rs = 0.171, p = 0.025) and H-FABP and age (rs = 0.293, p< 0.001).
The Scandinavian guidelines use age 65 years old as a risk factor.[5] After dichotomising
the cohort into< 65 (n = 129) and 65 years old (n = 43), both S100B and H-FABP showed
higher levels in patients 65 years old than in younger patients (p = 0.004 and p =<0.001,
respectively). Marker levels were investigated separately within the younger and older patient
groups. In the younger patient group, S100B showed 100% sensitivity and 8% specificity,
whereas H-FABP reached 100% sensitivity and 37% specificity. In the older patient group,
S100B displayed 100% sensitivity and 32% specificity, compared to H-FABP’s 100% sensitivity
and 8% specificity (Table 4).
Fig 1. ROC curves, 6 h post-trauma, for S100B and H-FABP, representing best performance when
set to: a) 100% sensitivity; b) 90%–100% sensitivity; and c) the S100B cut-off 0.1 μg/L.
https://doi.org/10.1371/journal.pone.0175572.g001
Table 3. Performances when sensitivity was set at 100%, in the 90%–100% range, and when S100B’s cut-off was set at 0.1 μg/L, with correspond-
ing NPV and PPV for patients 6 h post-trauma.
Protein Cut-off SE % (95% CI) SP % (95% CI) NPV PPV
S100B 0.042 100 (100–100) 6.4 (2.8–10.7) 100 19.6
0.071 90.6 (78.1–100) 19.3 (12.9–25.7) 90 20.4
0.1 81.3 (65.6–93.8) 42.1 (34.3–50.0) 92.6 25.2
H-FABP 2.62 100 (100–100) 29.3 (21.4–37.1) 100 22.4
SE, sensitivity; SP, specificity; NPV, negative predictive value; PPV, positive predictive value
https://doi.org/10.1371/journal.pone.0175572.t003
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The proteins diagnostic performance in patients with only isolated brain trauma was inves-
tigated. The cohort population decreased to 100 CT-negative and 24 CT-positive patients.
Within this subgroup of mTBI patients, both S100B and H-FABP were significantly increased
(p = 0.001) in CT-positive patients. At 100% sensitivity the S100B reached a specificity of 9%
whereas the H-FABP increased to 35%. The diagnostic performance was also investigated in
the small subpopulation of mTBI patients presenting multiple traumas. None of the proteins
had significantly different levels between CT-positive and CT-negative patients and the speci-
ficity decreased for both S100B and H-FABP, 5% and 18% respectively, when sensitivity was
set to 100% (Table 5).
All the results above were based on measurements 6 h after trauma. However, not all
patients seek help immediately and some are transferred from one medical facility to another,
increasing the time from trauma onset to blood sampling. The proteins’ predictive perfor-
mances were therefore also investigated on all the patients who arrived at the hospitals after an
mTBI event and within 24 h of trauma onset, with a mean time (± SD) of 250 min ± 172. The
number of mTBI patients included here was 261, of whom 41 (16%) were CT-positive (S4
Table). Both H-FABP and S100B levels remained significantly higher in the CT-positive
patients (p = 0.006 and p< 0.001, respectively). The proteins’ ability to differentiate CT-posi-
tive from CT-negative patients displayed similar results to those described for t 6 h: for
100% sensitivity, S100B reached 6% specificity and H-FABP reached 26% (S5 Table).
Discussion
This multicentre study evaluated H-FABP and S100B as potential protein biomarkers for dif-
ferentiating between CT-positive and CT-negative mTBI patients with GCS scores of 15 and at
least one clinical symptom. H-FABP reached 100% sensitivity and 29% specificity, whereas
S100B reached 100% sensitivity but only 6% specificity. The proteins’ performances were fur-
ther investigated when sensitivity was set in the 90%–100% range. Here, S100B reached a
specificity of 19% with a sensitivity of 91%. However, H-FABP performed better, with 100%
sensitivity and 29% specificity.
Table 4. The performances of H-FABP and S100B biomarkers at 100% sensitivity, 6 h post-trauma, dichotomised into younger and older
patients.
Age Protein CT-, n CT+, n Cut-off SE % (95% CI) SP % (95% CI)
< 65 S100B 115 14 0.042 100 (100–100) 7.8 (3.5–13.0)
H-FABP 115 14 2.74 100 (100–100) 36.5 (27.8–45.2)
 65 S100B 25 18 0.091 100 (100–100) 32.0 (16.0–52.0)
H-FABP 25 18 2.214 100 (100–100) 8.0 (0–20.0)
SE, sensitivity; SP, specificity
https://doi.org/10.1371/journal.pone.0175572.t004
Table 5. The performances of H-FABP and S100B biomarkers at 100% sensitivity, 6 h post-trauma in mTBI subgroups; isolated brain trauma or
multiple trauma patients.
Protein CT-, n CT+, n Cut-off SE % (95% CI) SP % (95% CI)
Isolated brain trauma S100B 100 24 0.052 100 (100–100) 9.0 (4.0–15.0)
H-FABP 100 24 2.62 100 (100–100) 35.0 (26.0–44.0)
Multiple trauma S100B 39 8 0.031 100 (100–100) 5.1 (0.0–12.8)
H-FABP 39 8 2.829 100 (100–100) 18.0 (7.7–30.8)
SE, sensitivity; SP, specificity
https://doi.org/10.1371/journal.pone.0175572.t005
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In parallel to biomarker research, guidelines are becoming increasingly interested in
improving care for mTBI patients based mainly on their GCS scores and risk factors.[3,5] The
WHO Collaborating Centre Task Force on mTBI suggested that patients with a GCS of 15 and
with one or more risk factors (e.g. age> 60 years old, vomiting, headache or amnesia) should
undergo a CT scan.[3] However, these guidelines still mean that there will be many CT-nega-
tive results. In the present study, 140 patients were CT-negative (81%), indicating the need for
a complementary decision-making aid. Scandinavian guidelines give similar recommenda-
tions, but they also suggest using the S100B biomarker with a cut-off level at 0.1 μg/L.[5] Here,
this recommended cut-off level only managed 81% sensitivity and 42% specificity, correspond-
ing to 6 false-negative patients.
Whereas S100B has been widely studied as a protein biomarker for diagnosis and decision
rules in mTBI patients, H-FABP is relatively unknown in this field. H-FABP is a small (15
kDa) cytoplasmic protein whose primary function is to transport long-chain fatty acids.[23] It
was first discovered in the heart, from where it got its name—heart fatty-acid binding protein.
[21] It is abundant in the cardiomyocytes and has been studied for many years as a diagnostic
tool for different heart conditions.[24,25] This small, intracellular molecule has also been
shown to be expressed in the grey matter and neuron cell bodies.[23] H-FABP has therefore
been highlighted as a potential brain injury biomarker for several diseases, such as Alzheimer’s,
Parkinson’s and stroke, and it has been shown to accurately predict the outcome in severe
TBI and be capable of differentiate between mTBI patients and controls.[18,20,22,23,25] The
H-FABP has been shown in stroke to have a rapid increase after symptom onset with a peak at
3h and slowly decrease during 5 days.[20] S100B on the other side has a rapid increase however
also a rapid decrease in concentration limiting the diagnostic time window.[26] The H-FABP
robustness over time makes it interesting as a diagnostic and perhaps also prognostic bio-
marker. The H-FABP kinetics can be an explanation to the results shown here where patients
up to 6h after trauma were included and showed similar results as those included up to 24h
after trauma.
S100B is a small (10 kDa), intracellular, calcium binding protein and is found abundantly
in astrocytes and adipocytes.[27] Because they are found in different locations, measuring
S100B and H-FABP in combination could be interesting. Previous studies in different fields
have highlighted the advantages of combining biomarkers into panels to increase their overall
performance.[28,29] We therefore combined S100B and H-FABP but used individual 100%
sensitivity cut-offs. The sensitivity remained at 100% and the specificity rose to 30%, similar to
the level of H-FABP alone. It would be interesting to investigate the differentiating perfor-
mance of these two molecules and age by using a multivariate analysis. Unfortunately, with
regard to the Monte Carlo method, the study population used here was too small.[30]
As different guidelines state, older age can be classified as a risk factor for intracranial
lesions.[3,5] Salottolo et al. showed that elderly people obtain worse GCS scores than younger
patients with the same type of injury severity, which might explain the significantly higher age
seen in the CT-positive population than in the CT-negative one.[31] The influence of age on
S100B and H-FABP has previously been demonstrated.[21,32–35] The Scandinavian guide-
lines highlighted that age 65 could be a risk factor for brain lesions.[5] The present cohort
was therefore separated into groups < 65 and 65 years old. In the younger patient group,
H-FABP showed even better performance than for the entire cohort, with sensitivity at 100%
and specificity of 37%. In the older patient group, however, the best performances at 100% sen-
sitivity were inversed, with S100B reaching 32% specificity and H-FABP only reaching 8%.
These results seem to indicate that H-FABP better discriminates between the CT scan groups
among younger patients and S100B does better among older ones. It has previously been
shown that H-FABP blood concentration tends to increase in elderly people possibly due to
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decrease in renal function.[35] This could explain the results shown here, where elderly CT-
negative patients will be classified as false positive using H-FABP. Due to the low number of
patients in each group, more research is needed to confirm these findings and potentially to
create an age ranking table of performances and cut-offs.
The tissue specificity is an important aspect to take under consideration when evaluating a
biomarker. Therefore, the differential diagnostic performance of both S100B and H-FABP in
mTBI patients with isolated and multiple trauma were evaluated. The capacity of differentiate
between CT-positive and CT-negative patients for both H-FABP and S100B decreased to 18%
and 5% specificity respectively for 100% sensitivity for patients with multiple traumas due to
high blood concentration in CT-negative patients. For mTBI patients with isolated brain
trauma the S100B slightly increased to 9% specificity when sensitivity was set to 100%. Inter-
estingly, the H-FABP performance rose to 100% sensitivity and 35% specificity. These results
are confirmed by previous studies in severe TBI showing H-FABP to have increased levels in
patients with multiple traumas compared to isolated brain traumas.[22]
Another factor that can interfere with biomarker utility is the time between trauma and
sample collection. Different earlier articles have used periods of< 3 h to< 6 h for the evalua-
tion of their biomarkers.[11,12,15] The time to hospital arrival has been shown to vary—
between the median direct admission time of 1 h and a delayed admission time of 4 h post-
trauma—depending on several criteria, such as gender, the influence of alcohol, low energy
trauma, and trauma at home or in a public place.[36] The present study’s main results were
therefore based on arrival 6 h post-trauma. However, 89 patients in our cohort arrived later
(6–24 h), 9 (10%) of whom were CT-positive, suggesting the need for a decision rule bio-
marker, even for this patient group. To reflect the real clinical situation as accurately as possi-
ble, we included all the patients who arrived at the emergency units within 24 h of trauma
onset. These enlarged inclusion criteria raised the cohort size to 261 patients. The results
obtained showed similar levels of performance to those observed for arrival 6 h post-trauma.
S100B measurement would only have suggested discharge for 6% of the CT-negative patients
while keeping all the CT-positive patients in the hospital; H-FABP measurement would have
suggested discharge for 26%. The results coincide with what could be expected seen from pre-
viously performed kinetic studies for both S100B and H-FABP. S100B has been shown to rap-
idly increase but also to decline early.[26] H-FABP’s property of remaining stable over time
has been demonstrated previously in stroke patients; the protein’s level increased early and
showed highest levels already 3h after symptom onset and elevated levels were maintained for
several days.[20] The results suggest that measuring H-FABP for a longer period of time post-
trauma could be of benefit to patients arriving a long time after their accident.
Even though this study showed the potential use of H-FABP as a brain injury biomarker for
differentiating between CT-positive and CT-negative patients, there were some study limita-
tions. Patients included within this study are a sub-population of a typical ER mTBI popula-
tion. This selection leads to a higher percentage of CT-positive patients mainly due to the
exclusion of CT-negative patients i.e. mTBI patients with GCS 15 and no additional clinical
symptom. Further limitation was the heterogeneity of the cohorts, due to the differences in
sample collection (serum and plasma), and the use of different immunoassays. Moreover, after
stratifying by age, the remaining sample size was small, and these results should be verified
and validated in a larger cohort.
Conclusion
The present prospective multicentre study compared the measurement of levels of heart fatty-
acid binding protein and S100B as potential tools to aid decision-making when clinicians need
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to objectively evaluate whether mTBI patients can be discharged without undergoing a CT
scan. S100B performed better for older patients ( 65 years old) and H-FABP performed bet-
ter for younger ones (< 65 years old). However, individual performance over the entire popu-
lation revealed that H-FABP was an interesting protein biomarker for differentiating between
CT-positive and CT-negative patients, within both 6 h and 24 h of trauma onset.
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